Sanofi is also running a fourth phase 3 trial called PERSEUS in patients with primary progressive MS (PPMS). Earlier this year, it abandoned its development in another neuromuscular disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback